Larvol Delta - Avenue-Therapeutics-Enters-into-a-Transformational-License-Agreement-with-AnnJi-Pharmaceutical-to-Develop-and-Commercialize-AJ201-a-FirstinClass-Clinical-Asset-for-the-Treatment-of-Spinal-and-Bulbar-Muscular-Atrophy

ALZ002 - AnnJi Pharma, Fortress

https://www.globenewswire.com/news-release/2023/03/02/2619293/0/en/Avenue-Therapeutics-Enters-into-a-Transformational-License-Agreement-with-AnnJi-Pharmaceutical-to-Develop-and-Commercialize-AJ201-a-First-in-Class-Clinical-Asset-for-the-Treatment-.html

Mar 2, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next